Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Neurotherapeutics
Published in: Neurotherapeutics 4/2021

01-10-2021 | Leprosy | Review

Treatment and Evaluation Advances in Leprosy Neuropathy

Authors: Gigi J. Ebenezer, David M. Scollard

Published in: Neurotherapeutics | Issue 4/2021

Login to get access

Abstract

Neuropathy and related disabilities are the major medical consequences of leprosy, which remains a global medical concern. Despite major advances in understanding the mechanisms of M. leprae entry into peripheral nerves, most aspects of the pathogenesis of leprosy neuropathy remain poorly understood. Sensory loss is characteristic of leprosy, but neuropathic pain is sometimes observed. Effective anti-microbial therapy is available, but neuropathy remains a problem especially if diagnosis and treatment are delayed. Currently there is intense interest in post-exposure prophylaxis with single-dose rifampin in endemic areas, as well as with enhanced prophylactic regimens in some situations. Some degree of nerve involvement is seen in all cases and neuritis may occur in the absence of leprosy reactions, but acute neuritis commonly accompanies both Type 1 and Type 2 leprosy reactions and may be difficult to manage. A variety of established as well as new methods for the early diagnosis and assessment of leprosy neuropathy are reviewed. Corticosteroids offer the primary treatment for neuritis and for subclinical neuropathy in leprosy, but success is limited if nerve function impairment is present at the time of diagnosis. A candidate vaccine has shown apparent benefit in preventing nerve injury in the armadillo model. The development of new therapeutics for leprosy neuropathy is greatly needed.
Appendix
Available only for authorised users
Literature
1.
Han, X.Y., Y.H. Seo, K.C. Sizer, T. Schoberle, G.S. May, J.S. Spencer, et al. A new Mycobacterium species causing diffuse lepromatous leprosy. Am J Clin Pathol 2008;130:(6):856–64.
2.
Sharma, R., P. Singh, R.C. McCoy, S.M. Lenz, K. Donovan, M.T. Ochoa, et al. Isolation of Mycobacterium lepromatosis and Development of Molecular Diagnostic Assays to Distinguish Mycobacterium leprae and M. lepromatosis. Clin Infect Dis 2020;71:(8):e262-e269.
3.
Ridley, D.S. Histological classification and the immunological spectrum of leprosy. Bull World Health Organ 1974;51:(5):451–65.
4.
Ridley, D.S. and W.H. Jopling. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis 1966;34:(3):255–73.
5.
WHO Expert Committee on Leprosy., WHO Expert Committee on Leprosy : sixth report. World Health Organization technical report series,. 1988, Geneva: World Health Organization. 51 p.
6.
Dastur, D.K. Cutaneous nerves in leprosy; the relationship between histopathology and cutaneous sensibility. Brain 1955;78:(4):615–33.
7.
Srinivas, G., T. Muthuvel, V. Lal, K. Vaikundanathan, E.M. Schwienhorst-Stich, and C. Kasang. Risk of disability among adult leprosy cases and determinants of delay in diagnosis in five states of India: A case-control study. PLoS Negl Trop Dis 2019;13:(6):e0007495.
8.
Moschioni, C., C.M. Antunes, M.A. Grossi, and J.R. Lambertucci. Risk factors for physical disability at diagnosis of 19,283 new cases of leprosy. Rev Soc Bras Med Trop 2010;43:(1):19–22.
9.
Daniel, E., T.J. Ffytche, J.H. Kempen, P.S. Rao, M. Diener-West, and P. Courtright. Incidence of ocular complications in patients with multibacillary leprosy after completion of a 2 year course of multidrug therapy. Br J Ophthalmol 2006;90:(8):949–54.
10.
Ebenezer, G.J. and E. Daniel. Expression of protein gene product 9.5 in lepromatous eyes showing ciliary body nerve damage and a "dying back" phenomenon in the posterior ciliary nerves. Br J Ophthalmol 2004;88:(2):178–81.
11.
Zhao, C., S. Lu, N. Tajouri, A. Dosso, and A.B. Safran. In vivo confocal laser scanning microscopy of corneal nerves in leprosy. Arch Ophthalmol 2008;126:(2):282–4.
12.
Ebenezer, G.J., S. Arumugam, and C.K. Job. Infection by M. leprae is governed by the temperature at the entry point: a preliminary note. Int J Lepr Other Mycobact Dis 1999;67:(2):162–4.
13.
Drutz, D.J., T.S. Chen, and W.H. Lu. The continuous bacteremia of lepromatous leprosy. N Engl J Med 1972;287:(4):159–64.
14.
Raval, S.N., U. Sengupta, G. Ramu, P.V. Prabhune, and K.V. Desikan. A study of continuous bacillaemia in borderline and lepromatous type of leprosy. Lepr India 1982;54:(4):623–33.
15.
McDougall, A.C., R.J. Rees, A.G. Weddell, and M.W. Kanan. The histopathology of lepromatous leprosy in the nose. J Pathol 1975;115:(4):215–26.
16.
Scollard, D.M. Endothelial cells and the pathogenesis of lepromatous neuritis:insights from the armadillo model. Microbes Infect 2000;2:(15):1835–43.
17.
Scollard, D.M., G. McCormick, and J.L. Allen. Localization of Mycobacterium leprae to endothelial cells of epineurial and perineurial blood vessels and lymphatics. Am J Pathol 1999;154:(5):1611–20.
18.
Brand, P.W. Temperature variation and leprosy deformity. Int J Lepr 1959;27:(1):1–7.
19.
Hastings, R.C., P.W. Brand, R.E. Mansfield, and J.D. Ebner. Bacterial density in the skin in lepromatous leprosy as related to temperature. Lepr Rev 1968;39:(2):71–4.
20.
Sabin, T.D., E.R. Hackett, and P.W. Brand. Temperatures along the course of certain nerves often affected in lepromatous leprosy. Int J Lepr Other Mycobact Dis 1974;42:(1):38–42.
21.
Rambukkana, A. Molecular basis for the peripheral nerve predilection of Mycobacterium leprae. Curr Opin Microbiol 2001;4:(1):21–7.
22.
Rambukkana, A., J.L. Salzer, P.D. Yurchenco, and E.I. Tuomanen. Neural targeting of Mycobacterium leprae mediated by the G domain of the laminin-alpha2 chain. Cell 1997;88:(6):811–21.
23.
Rambukkana, A., H. Yamada, G. Zanazzi, T. Mathus, J.L. Salzer, P.D. Yurchenco, et al. Role of alpha-dystroglycan as a Schwann cell receptor for Mycobacterium leprae. Science 1998;282:(5396):2076–9.
24.
Hess, S. and A. Rambukkana. Cell Biology of Intracellular Adaptation of Mycobacterium leprae in the Peripheral Nervous System. Microbiol Spectr 2019;7:(4).
25.
Spierings, E., T. De Boer, L. Zulianello, and T.H. Ottenhoff. Novel mechanisms in the immunopathogenesis of leprosy nerve damage: the role of Schwann cells, T cells and Mycobacterium leprae. Immunol Cell Biol 2000;78:(4):349–55.
26.
Rambukkana, A. Mycobacterium leprae-induced demyelination: a model for early nerve degeneration. Curr Opin Immunol 2004;16:(4):511–8.
27.
Chandi, S.M. and C.K. Job. The early cellular response to M. leprae. An ultrastructural study. Lepr India 1978;50:(3):345–57.
28.
Sherman, D.L., C. Fabrizi, C.S. Gillespie, and P.J. Brophy. Specific disruption of a schwann cell dystrophin-related protein complex in a demyelinating neuropathy. Neuron 2001;30:(3):677–87.
29.
Madigan, C.A., C.J. Cambier, K.M. Kelly-Scumpia, P.O. Scumpia, T.Y. Cheng, J. Zailaa, et al. A Macrophage Response to Mycobacterium leprae Phenolic Glycolipid Initiates Nerve Damage in Leprosy. Cell 2017;170:(5):973–985 e10.
30.
Oliveira, A.L., S.L. Antunes, R.M. Teles, A.C. Costa da Silva, T.P. Silva, R. Brandao Teles, et al. Schwann cells producing matrix metalloproteinases under Mycobacterium leprae stimulation may play a role in the outcome of leprous neuropathy. J Neuropathol Exp Neurol 2010;69:(1):27–39.
31.
Croft, R.P., P.G. Nicholls, J.H. Richardus, and W.C. Smith. Incidence rates of acute nerve function impairment in leprosy: a prospective cohort analysis after 24 months (The Bangladesh Acute Nerve Damage Study). Lepr Rev 2000;71:(1):18–33.
32.
Scollard, D.M., R.W. Truman, and G.J. Ebenezer. Mechanisms of nerve injury in leprosy. Clin Dermatol 2015;33:(1):46–54.
33.
Chandi, S.M., C.J. Chacko, E.P. Fritschi, and C.K. Job. Segmental necrotizing granulomatous neuritis of leprosy. Int J Lepr Other Mycobact Dis 1980;48:(1):41–7.
34.
Santos, D.F.D., M.R. Mendonca, D.E. Antunes, E.F.P. Sabino, R.C. Pereira, L.R. Goulart, et al. Revisiting primary neural leprosy: Clinical, serological, molecular, and neurophysiological aspects. PLoS Negl Trop Dis 2017;11:(11):e0006086.
35.
Serrano-Coll, H., O. Mieles, C. Escorcia, A. Diaz, C. Beltran, and N. Cardona-Castro. [A case series of pure neural leprosy in patients diagnosed in a specialized center for the control of Hansen's disease in Colombia]. Biomedica 2018;38:(2):153–161.
36.
Shukla, B., R. Verma, V. Kumar, M. Kumar, K.P. Malhotra, R.K. Garg, et al. Pathological, ultrasonographic, and electrophysiological characterization of clinically diagnosed cases of pure neuritic leprosy. J Peripher Nerv Syst 2020;25:(2):191–203.
37.
Haroun, O.M.O., J. Vollert, D.N. Lockwood, D.L.H. Bennett, V.V. Pai, V. Shetty, et al. Clinical characteristics of neuropathic pain in leprosy and associated somatosensory profiles: a deep phenotyping study in India. Pain Rep 2019;4:(6):e743.
38.
van Brakel, W.H., P.G. Nicholls, L. Das, P. Barkataki, S.K. Suneetha, R.S. Jadhav, et al. The INFIR Cohort Study: investigating prediction, detection and pathogenesis of neuropathy and reactions in leprosy. Methods and baseline results of a cohort of multibacillary leprosy patients in north India. Lepr Rev 2005;76:(1):14–34.
39.
Saunderson, P. The epidemiology of reactions and nerve damage. Lepr Rev 2000;71 SupplS106–10.
40.
Scollard, D.M., C.M. Martelli, M.M. Stefani, F. Maroja Mde, L. Villahermosa, F. Pardillo, et al. Risk factors for leprosy reactions in three endemic countries. Am J Trop Med Hyg 2015;92:(1):108–14.
41.
van Brakel, W.H. and I.B. Khawas. Silent neuropathy in leprosy: an epidemiological description. Lepr Rev 1994;65:(4):350–60.
42.
van Brakel, W.H., P.G. Nicholls, E.P. Wilder-Smith, L. Das, P. Barkataki, D.N. Lockwood, et al. Early diagnosis of neuropathy in leprosy--comparing diagnostic tests in a large prospective study (the INFIR cohort study). PLoS Negl Trop Dis 2008;2:(4):e212.
43.
Wagenaar, I., W. Brandsma, E. Post, W. van Brakel, D. Lockwood, P. Nicholls, et al. Two randomized controlled clinical trials to study the effectiveness of prednisolone treatment in preventing and restoring clinical nerve function loss in leprosy: the TENLEP study protocols. BMC Neurol 2012;12159.
44.
Cooreman, E.A., Leprosy/Hansen Disease: Management of reactions and prevention of disabilities. 2020: World Health Organization. 72.
45.
Haroun, O.M.O., A. Hietaharju, E. Bizuneh, F. Tesfaye, W.J. Brandsma, M. Haanpaa, et al. Investigation of neuropathic pain in treated leprosy patients in Ethiopia: a cross-sectional study. Pain 2012;153:(8):1620–1624.
46.
Raicher, I., P. Stump, S.B. Harnik, R.A. de Oliveira, R. Baccarelli, L. Marciano, et al. Neuropathic pain in leprosy: symptom profile characterization and comparison with neuropathic pain of other etiologies. Pain Rep 2018;3:(2):e638.
47.
Lasry-Levy, E., A. Hietaharju, V. Pai, R. Ganapati, A.S. Rice, M. Haanpaa, et al. Neuropathic pain and psychological morbidity in patients with treated leprosy: a cross-sectional prevalence study in Mumbai. PLoS Negl Trop Dis 2011;5:(3):e981.
48.
Faget, G.H. and P.T. Erickson. Leprosy chemotherapy. Am Clin 1948;12:(6):503–10.
49.
Alemu Belachew, W. and B. Naafs. Position statement: LEPROSY: Diagnosis, treatment and follow-up. J Eur Acad Dermatol Venereol 2019;33:(7):1205–1213.
50.
Lowe, J. Treatment of leprosy with diamino-diphenyl sulphone by mouth. Lancet 1950;1:(6596):145–50.
51.
Pearson, J.M., R.J. Rees, and M.F. Waters. Sulphone resistance in leprosy. A review of one hundred proven clinical cases. Lancet 1975;2:(7924):69–72.
52.
WHO Study Group on Chemotherapy of Leprosy. and World Health Organization., Chemotherapy of leprosy : report of a WHO study group. WHO technical report series,. 1994, Geneva: World Health Organization. v, 24 p.
53.
Daniel, E., G.J. Ebenezer, and C.K. Job. Pathology of iris in leprosy. Br J Ophthalmol 1997;81:(6):490–2.
54.
Sivaprasad, N., S. Snehalatha, D. Lobo, M. Aschhoff, and C.K. Job. Viability of Mycobacterium leprae in lepromatous patients after five years of dapsone monotherapy supplemented with two years of multidrug therapy. Indian J Lepr 1995;67:(4):427–33.
55.
Gillis, T.P. and D.L. Williams. Dapsone resistance in Mycobacterium leprae. Lepr Rev 2000;71 SupplS91–5.
56.
Williams, D.L., L. Spring, E. Harris, P. Roche, and T.P. Gillis. Dihydropteroate synthase of Mycobacterium leprae and dapsone resistance. Antimicrob Agents Chemother 2000;44:(6):1530–7.
57.
Shepard, C.C., J.G. Tolentino, and D.H. McRae. The therapeutic effect of 4,4'-diacetyldiamino-diphenylsulfone (DADDS) in leprosy. Am J Trop Med Hyg 1968;17:(2):192–201.
58.
Chemotherapy of leprosy for control programmes. World Health Organ Tech Rep Ser 1982;6751–33.
59.
Rees, R.J. Chemotherapy of leprosy for control programmes: scientific basis and practical application. Lepr Rev 1983;54:(2):81–7.
60.
Ebenezer, G.J., S. Daniel, G. Norman, E. Daniel, and C.K. Job. Are viable Mycobacterium leprae present in lepromatous patients after completion of 12 months' and 24 months' multi-drug therapy? Indian J Lepr 2004;76:(3):199–206.
61.
Levy, L., C.C. Shepard, and P. Fasal. The bactericidal effect of rifampicin on M. leprae in man: a) single doses of 600, 900 and 1200 mg; and b) daily doses of 300 mg. Int J Lepr Other Mycobact Dis 1976;44:(1–2):183–7.
62.
Shetty, V.P., A. Wakade, and N.H. Antia. A high incidence of viable Mycobacterium leprae in post-MDT recurrent lesions in tuberculoid leprosy patients. Lepr Rev 2001;72:(3):337–44.
63.
Ji, B., E.G. Perani, C. Petinom, L. N'Deli, and J.H. Grosset. Clinical trial of ofloxacin alone and in combination with dapsone plus clofazimine for treatment of lepromatous leprosy. Antimicrob Agents Chemother 1994;38:(4):662–7.
64.
De Bruyn, E.E., H.C. Steel, E.J. Van Rensburg, and R. Anderson. The riminophenazines, clofazimine and B669, inhibit potassium transport in gram-positive bacteria by a lysophospholipid-dependent mechanism. J Antimicrob Chemother 1996;38:(3):349–62.
65.
Penna, M.L., S. Buhrer-Sekula, M.A. Pontes, R. Cruz, S. Goncalves Hde, and G.O. Penna. Results from the clinical trial of uniform multidrug therapy for leprosy patients in Brazil (U-MDT/CT-BR): decrease in bacteriological index. Lepr Rev 2014;85:(4):262–6.
66.
Butlin, C.R., D. Pahan, A.K.J. Maug, S. Withington, P. Nicholls, K. Alam, et al. Outcome of 6 months MBMDT in MB patients in Bangladesh- preliminary results. Lepr Rev 2016;87:(2):171–82.
67.
Lazo-Porras, M., G.J. Prutsky, P. Barrionuevo, J.C. Tapia, C. Ugarte-Gil, O.J. Ponce, et al. World Health Organization (WHO) antibiotic regimen against other regimens for the treatment of leprosy: a systematic review and meta-analysis. BMC Infect Dis 2020;20:(1):62.
68.
Matsuoka, M., Y. Kashiwabara, and M. Namisato. A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin. Int J Lepr Other Mycobact Dis 2000;68:(4):452–5.
69.
Sekar, B., N. Elangeswaran, E. Jayarama, M. Rajendran, S.S. Kumar, R. Vijayaraghavan, et al. Drug susceptibility of Mycobacterium leprae: a retrospective analysis of mouse footpad inoculation results from 1983 to 1997. Lepr Rev 2002;73:(3):239–44.
70.
Williams, D.L., C. Lewis, F.G. Sandoval, N. Robbins, S. Keas, T.P. Gillis, et al. Drug resistance in patients with leprosy in the United States. Clin Infect Dis 2014;58:(1):72–3.
71.
Cambau, E., E. Perani, I. Guillemin, P. Jamet, and B. Ji. Multidrug-resistance to dapsone, rifampicin, and ofloxacin in Mycobacterium leprae. Lancet 1997;349:(9045):103–4.
72.
Ebenezer, G.J., G. Norman, G.A. Joseph, S. Daniel, and C.K. Job. Drug resistant-Mycobacterium leprae--results of mouse footpad studies from a laboratory in south India. Indian J Lepr 2002;74:(4):301–12.
73.
Mahajan, N.P., M. Lavania, I. Singh, S. Nashi, V. Preethish-Kumar, S. Vengalil, et al. Evidence for Mycobacterium leprae Drug Resistance in a Large Cohort of Leprous Neuropathy Patients from India. Am J Trop Med Hyg 2020;102:(3):547–552.
74.
Balagon, M.F., R.V. Cellona, E. Cruz, J.A. Burgos, R.M. Abalos, G.P. Walsh, et al. Long-term relapse risk of multibacillary leprosy after completion of 2 years of multiple drug therapy (WHO-MDT) in Cebu, Philippines. Am J Trop Med Hyg 2009;81:(5):895–9.
75.
Shetty, V.P., M.W. Uplekar, and N.H. Antia. Primary resistance to single and multiple drugs in leprosy--a mouse footpad study. Lepr Rev 1996;67:(4):280–6.
76.
Norman, G., G. Joseph, G. Ebenezer, S.P. Rao, and C.K. Job. Secondary rifampin resistance following multi-drug therapy--a case report. Int J Lepr Other Mycobact Dis 2003;71:(1):18–21.
77.
Hooper, D.C. Mechanisms of action and resistance of older and newer fluoroquinolones. Clin Infect Dis 2000;31 Suppl 2S24–8.
78.
Matrat, S., S. Petrella, E. Cambau, W. Sougakoff, V. Jarlier, and A. Aubry. Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones. Antimicrob Agents Chemother 2007;51:(5):1643–8.
79.
Girdhar, B.K. Fluoroquinolones and their adverse effects. Indian J Lepr 1993;65:(1):69–79.
80.
Ji, B., E.G. Perani, and J.H. Grosset. Effectiveness of clarithromycin and minocycline alone and in combination against experimental Mycobacterium leprae infection in mice. Antimicrob Agents Chemother 1991;35:(3):579–81.
81.
Gelber, R.H., P. Siu, M. Tsang, and L.P. Murray. Activities of various macrolide antibiotics against Mycobacterium leprae infection in mice. Antimicrob Agents Chemother 1991;35:(4):760–3.
82.
Meier, A., L. Heifets, R.J. Wallace, Jr., Y. Zhang, B.A. Brown, P. Sander, et al. Molecular mechanisms of clarithromycin resistance in Mycobacterium avium: observation of multiple 23S rDNA mutations in a clonal population. J Infect Dis 1996;174:(2):354–60.
83.
Gelber, R.H. Activity of minocycline in Mycobacterium leprae-infected mice. J Infect Dis 1987;156:(1):236–9.
84.
Taylor, D.E. and A. Chau. Tetracycline resistance mediated by ribosomal protection. Antimicrob Agents Chemother 1996;40:(1):1–5.
85.
Ji, B., E.G. Perani, C. Petinom, and J.H. Grosset. Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice. Antimicrob Agents Chemother 1996;40:(2):393–9.
86.
Setia, M.S., S.S. Shinde, H.R. Jerajani, and J.F. Boivin. Is there a role for rifampicin, ofloxacin and minocycline (ROM) therapy in the treatment of leprosy? Systematic review and meta-analysis. Trop Med Int Health 2011;16:(12):1541–51.
87.
Villahermosa, L.G., T.T. Fajardo, Jr., R.M. Abalos, R.V. Cellona, M.V. Balagon, E.C. Dela Cruz, et al. Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy. Am J Trop Med Hyg 2004;70:(2):197–200.
88.
Kumar, A., A. Girdhar, and B.K. Girdhar. A randomized controlled trial to compare cure and relapse rate of paucibacillary multidrug therapy with monthly rifampicin, ofloxacin, and minocycline among paucibacillary leprosy patients in Agra District, India. Indian J Dermatol Venereol Leprol 2015;81:(4):356–62.
89.
Lockwood, D.N. and G. Cunha Mda. Developing new MDT regimens for MB patients; time to test ROM 12 month regimens globally. Lepr Rev 2012;83:(3):241–4.
90.
Ebenezer, G.J. and C.K. Job. Histopathological activity in paucibacillary leprosy patients after ROM therapy. Int J Lepr Other Mycobact Dis 1999;67:(4):409–13.
91.
Moet, F.J., D. Pahan, L. Oskam and J.H. Richardus. Effectiveness of single dose rifampicin in preventing leprosy in close contacts of patients with newly diagnosed leprosy: cluster randomised controlled trial. BMJ 2008;336:(7647):761-4.
92.
Schoenmakers, A., L. Mieras, T. Budiawan, and W.H. van Brakel. The State of Affairs in Post-Exposure Leprosy Prevention: A Descriptive Meta-Analysis on Immuno- and Chemo-Prophylaxis. Res Rep Trop Med 2020;1197–117.
93.
Lockwood, D.N.J., P. Krishnamurthy, B. Kumar, and G. Penna. Single-dose rifampicin chemoprophylaxis protects those who need it least and is not a cost-effective intervention. PLoS Negl Trop Dis 2018;12:(6):e0006403.
94.
Mieras, L.F., A.T. Taal, W.H. van Brakel, E. Cambau, P.R. Saunderson, W.C.S. Smith, et al. An enhanced regimen as post-exposure chemoprophylaxis for leprosy: PEP+. BMC Infect Dis 2018;18:(1):506.
95.
Lipworth, B.J. Therapeutic implications of non-genomic glucocorticoid activity. Lancet 2000;356:(9224):87–9.
96.
Newton, R. Molecular mechanisms of glucocorticoid action: what is important? Thorax 2000;55:(7):603–13.
97.
Ayroldi, E., L. Cannarile, G. Migliorati, G. Nocentini, D.V. Delfino, and C. Riccardi. Mechanisms of the anti-inflammatory effects of glucocorticoids: genomic and nongenomic interference with MAPK signaling pathways. FASEB J 2012;26:(12):4805–20.
98.
Stahn, C. and F. Buttgereit. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol 2008;4:(10):525–33.
99.
Rao, P.S., D.S. Sugamaran, J. Richard, and W.C. Smith. Multi-centre, double blind, randomized trial of three steroid regimens in the treatment of type-1 reactions in leprosy. Lepr Rev 2006;77:(1):25–33.
100.
Naafs, B. Bangkok Workshop on Leprosy Research. Treatment of reactions and nerve damage. Int J Lepr Other Mycobact Dis 1996;64:(4 Suppl):S21–8.
101.
Naafs, B. Treatment duration of reversal reaction: a reappraisal. Back to the past. Lepr Rev 2003;74:(4):328–36.
102.
Walker, S.L., P.G. Nicholls, S. Dhakal, R.A. Hawksworth, M. Macdonald, K. Mahat, et al. A phase two randomised controlled double blind trial of high dose intravenous methylprednisolone and oral prednisolone versus intravenous normal saline and oral prednisolone in individuals with leprosy type 1 reactions and/or nerve function impairment. PLoS Negl Trop Dis 2011;5:(4):e1041.
103.
Pai, V.V., P.U. Tayshetye, and R. Ganapati. A study of standardized regimens of steroid treatment in reactions in leprosy at a referral centre. Indian J Lepr 2012;84:(1):9–15.
104.
Saunderson, P., S. Gebre, K. Desta, P. Byass, and D.N. Lockwood. The pattern of leprosy-related neuropathy in the AMFES patients in Ethiopia: definitions, incidence, risk factors and outcome. Lepr Rev 2000;71:(3):285–308.
105.
Croft, R.P., J.H. Richardus, and W.C. Smith. Field treatment of acute nerve function impairment in leprosy using a standardized corticosteroid regimen--first year's experience with 100 patients. Lepr Rev 1997;68:(4):316–25.
106.
van Brakel, W.H. and I.B. Khawas. Nerve function impairment in leprosy: an epidemiological and clinical study--Part 2: Results of steroid treatment. Lepr Rev 1996;67:(2):104–18.
107.
Richardus, J.H., S.G. Withington, A.M. Anderson, R.P. Croft, P.G. Nicholls, W.H. Van Brakel, et al. Treatment with corticosteroids of long-standing nerve function impairment in leprosy: a randomized controlled trial (TRIPOD 3). Lepr Rev 2003;74:(4):311–8.
108.
Wagenaar, I., E. Post, W. Brandsma, B. Bowers, K. Alam, V. Shetty, et al. Effectiveness of 32 versus 20 weeks of prednisolone in leprosy patients with recent nerve function impairment: A randomized controlled trial. PLoS Negl Trop Dis 2017;11:(10):e0005952.
109.
Smith, W.C., A.M. Anderson, S.G. Withington, W.H. van Brakel, R.P. Croft, P.G. Nicholls, et al. Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomised placebo controlled trial (TRIPOD 1). BMJ 2004;328:(7454):1459.
110.
Walker, S.L., E. Lebas, S.N. Doni, D.N. Lockwood, and S.M. Lambert. The mortality associated with erythema nodosum leprosum in Ethiopia: a retrospective hospital-based study. PLoS Negl Trop Dis 2014;8:(3):e2690.
111.
de Barros, B., S.M. Lambert, M. Shah, V.V. Pai, J. Darlong, B.J. Rozario, et al. Methotrexate and prednisolone study in erythema nodosum leprosum (MaPs in ENL) protocol: a double-blind randomised clinical trial. BMJ Open 2020;10:(11):e037700.
112.
Ramu, G. and A. Girdhar. Treatment of steroid dependant cases of recurrent lepra reaction with a combination of thalidomide and clofazimine. Lepr India 1979;51:(4):497–504.
113.
Lambert, S.M., S.D. Nigusse, D.T. Alembo, S.L. Walker, P.G. Nicholls, M.H. Idriss, et al. Comparison of Efficacy and Safety of Ciclosporin to Prednisolone in the Treatment of Erythema Nodosum Leprosum: Two Randomised, Double Blind, Controlled Pilot Studies in Ethiopia. PLoS Negl Trop Dis 2016;10:(2):e0004149.
114.
Lambert, S.M., D.T. Alembo, S.D. Nigusse, L.K. Yamuah, S.L. Walker, and D.N. Lockwood. A Randomized Controlled Double Blind Trial of Ciclosporin versus Prednisolone in the Management of Leprosy Patients with New Type 1 Reaction, in Ethiopia. PLoS Negl Trop Dis 2016;10:(4):e0004502.
115.
Marlowe, S.N., R.A. Hawksworth, C.R. Butlin, P.G. Nicholls, and D.N. Lockwood. Clinical outcomes in a randomized controlled study comparing azathioprine and prednisolone versus prednisolone alone in the treatment of severe leprosy type 1 reactions in Nepal. Trans R Soc Trop Med Hyg 2004;98:(10):602–9.
116.
Sena, C.B., C.G. Salgado, C.M. Tavares, C.A. Da Cruz, M.B. Xavier, and J.L. Do Nascimento. Cyclosporine A treatment of leprosy patients with chronic neuritis is associated with pain control and reduction in antibodies against nerve growth factor. Lepr Rev 2006;77:(2):121–9.
117.
Lockwood, D.N., J. Darlong, P. Govindharaj, R. Kurian, P. Sundarrao, and A.S. John. AZALEP a randomized controlled trial of azathioprine to treat leprosy nerve damage and Type 1 reactions in India: Main findings. PLoS Negl Trop Dis 2017;11:(3):e0005348.
118.
Scollard, D.M., M.P. Joyce, and T.P. Gillis. Development of leprosy and type 1 leprosy reactions after treatment with infliximab: a report of 2 cases. Clin Infect Dis 2006;43:(2):e19–22.
119.
Deps, P.D. and D.N. Lockwood. Leprosy occurring as immune reconstitution syndrome. Trans R Soc Trop Med Hyg 2008;102:(10):966–8.
120.
Walker, S.L., A.M. Sales, C.R. Butlin, M. Shah, A. Maghanoy, S.M. Lambert, et al. A leprosy clinical severity scale for erythema nodosum leprosum: An international, multicentre validation study of the ENLIST ENL Severity Scale. PLoS Negl Trop Dis 2017;11:(7):e0005716.
121.
Chan, E.S. and B.N. Cronstein. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002;4:(4):266–73.
122.
Jakeman, P. and W.C. Smith. Thalidomide in leprosy reaction. Lancet 1994;343:(8895):432–3.
123.
Putinatti, M.S., J.C. Lastoria, and C.R. Padovani. Prevention of repeated episodes of type 2 reaction of leprosy with the use of thalidomide 100 mg/day. An Bras Dermatol 2014;89:(2):266–72.
124.
Cogen, A.L., E. Lebas, B. De Barros, J.P. Harnisch, W.R. Faber, D.N. Lockwood, et al. Biologics in Leprosy: A Systematic Review and Case Report. Am J Trop Med Hyg 2020;102:(5):1131–1136.
125.
Talwar, G.P., S.A. Zaheer, R. Mukherjee, R. Walia, R.S. Misra, A.K. Sharma, et al. Immunotherapeutic effects of a vaccine based on a saprophytic cultivable mycobacterium, Mycobacterium w in multibacillary leprosy patients. Vaccine 1990;8:(2):121–9.
126.
Katoch, K., V.M. Katoch, M. Natrajan, Sreevatsa, U.D. Gupta, V.D. Sharma, et al. 10–12 years follow-up of highly bacillated BL/LL leprosy patients on combined chemotherapy and immunotherapy. Vaccine 2004;22:(27–28):3649–57.
127.
Zaheer, S.A., R. Mukherjee, B. Ramkumar, R.S. Misra, A.K. Sharma, H.K. Kar, et al. Combined multidrug and Mycobacterium w vaccine therapy in patients with multibacillary leprosy. J Infect Dis 1993;167:(2):401–10.
128.
Duppre, N.C., L.A. Camacho, S.S. da Cunha, C.J. Struchiner, A.M. Sales, J.A. Nery, et al. Effectiveness of BCG vaccination among leprosy contacts: a cohort study. Trans R Soc Trop Med Hyg 2008;102:(7):631–8.
129.
Richardus, R.A., C.R. Butlin, K. Alam, K. Kundu, A. Geluk, and J.H. Richardus. Clinical manifestations of leprosy after BCG vaccination: an observational study in Bangladesh. Vaccine 2015;33:(13):1562–7.
130.
Coler, R.N., S. Bertholet, M. Moutaftsi, J.A. Guderian, H.P. Windish, S.L. Baldwin, et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One 2011;6:(1):e16333.
131.
Knudsen, N.P., A. Olsen, C. Buonsanti, F. Follmann, Y. Zhang, R.N. Coler, et al. Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens. Sci Rep 2016;619570.
132.
Duthie, M.S., W. Goto, G.C. Ireton, S.T. Reece, L.H. Sampaio, A.B. Grassi, et al. Antigen-specific T-cell responses of leprosy patients. Clin Vaccine Immunol 2008;15:(11):1659–65.
133.
Coler, R.N., M.S. Duthie, K.A. Hofmeyer, J. Guderian, L. Jayashankar, J. Vergara, et al. From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE. Clin Transl Immunology 2015;4:(4):e35.
134.
Duthie, M.S., M.T. Pena, G.J. Ebenezer, T.P. Gillis, R. Sharma, K. Cunningham, et al. LepVax, a defined subunit vaccine that provides effective pre-exposure and post-exposure prophylaxis of M. leprae infection. NPJ Vaccines 2018;312.
135.
Duthie, M.S., A. Frevol, T. Day, R.N. Coler, J. Vergara, T. Rolf, et al. A phase 1 antigen dose escalation trial to evaluate safety, tolerability and immunogenicity of the leprosy vaccine candidate LepVax (LEP-F1 + GLA-SE) in healthy adults. Vaccine 2020;38:(7):1700–1707.
136.
Job, C.K. and C.J. Chacko. A modification of Fite's stain for demonstration of M. leprae in tissue sections. Indian J Lepr 1986;58:(1):17–8.
137.
Nayak, S.V., A.S. Shivarudrappa, and A.S. Mukkamil. Role of fluorescent microscopy in detecting Mycobacterium leprae in tissue sections. Ann Diagn Pathol 2003;7:(2):78–81.
138.
Natrajan, M., K. Katoch, V.M. Katoch, and V.P. Bharadwaj. Enhancement in the histological diagnosis of indeterminate leprosy by demonstration of mycobacterial antigens. Acta Leprol 1995;9:(4):201–7.
139.
Job, C.K., V. Drain, A.T. Deming, R.C. Hastings, and M.A. Gerber. Role of S-100 protein as a marker for Schwann cells in the diagnosis of tuberculoid leprosy. Int J Lepr Other Mycobact Dis 1990;58:(2):392–3.
140.
Truman, R.W., C.K. Job, and R.C. Hastings. Antibodies to the phenolic glycolipid-1 antigen for epidemiologic investigations of enzootic leprosy in armadillos (Dasypus novemcinctus). Lepr Rev 1990;61:(1):19–24.
141.
Thomas, M.M., M. Jacob, S.M. Chandi, S. George, S. Pulimood, L. Jeyaseelan, et al. Role of S-100 staining in differentiating leprosy from other granulomatous diseases of the skin. Int J Lepr Other Mycobact Dis 1999;67:(1):1–5.
142.
Truman, R.W., G.J. Ebenezer, M.T. Pena, R. Sharma, G. Balamayooran, T.H. Gillingwater, et al. The armadillo as a model for peripheral neuropathy in leprosy. ILAR J 2014;54:(3):304–14.
143.
Stefani, M.M.A., C. Avanzi, S. Buhrer-Sekula, A. Benjak, C. Loiseau, P. Singh, et al. Whole genome sequencing distinguishes between relapse and reinfection in recurrent leprosy cases. PLoS Negl Trop Dis 2017;11:(6):e0005598.
144.
Ooi, W. and S. Saini. Diagnostic Pitfalls in an Atypical Case of Primary Neuritic Leprosy. Am J Trop Med Hyg 2021.
145.
Lockwood, D.N., S.B. Lucas, K.V. Desikan, G. Ebenezer, S. Suneetha, and P. Nicholls. The histological diagnosis of leprosy type 1 reactions: identification of key variables and an analysis of the process of histological diagnosis. J Clin Pathol 2008;61:(5):595–600.
146.
Lauria, G., S.T. Hsieh, O. Johansson, W.R. Kennedy, J.M. Leger, S.I. Mellgren, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2010;17:(7):903–12, e44–9.
147.
Mangus, L.M., D.B. Rao, and G.J. Ebenezer. Intraepidermal Nerve Fiber Analysis in Human Patients and Animal Models of Peripheral Neuropathy: A Comparative Review. Toxicol Pathol 2020;48:(1):59–70.
148.
Ebenezer, G.J., P. Hauer, C. Gibbons, J.C. McArthur, and M. Polydefkis. Assessment of epidermal nerve fibers: a new diagnostic and predictive tool for peripheral neuropathies. J Neuropathol Exp Neurol 2007;66:(12):1059–73.
149.
Rodrigues Junior, I.A., I.C. Silva, L.T. Gresta, S. Lyon, F. Villarroel Mde, and R.M. Arantes. Degree of skin denervation and its correlation to objective thermal sensory test in leprosy patients. PLoS Negl Trop Dis 2012;6:(12):e1975.
150.
Facer, P., D. Mann, R. Mathur, S. Pandya, U. Ladiwala, B. Singhal, et al. Do nerve growth factor-related mechanisms contribute to loss of cutaneous nociception in leprosy? Pain 2000;85:(1–2):231–8.
151.
Antunes, S.L., Y. Liang, J.A. Neri, M. Haak-Frendscho, and O. Johansson. The expression of NGFr and PGP 9.5 in leprosy reactional cutaneous lesions: an assessment of the nerve fiber status using immunostaining. Arq Neuropsiquiatr 2003;61:(2B):346–52.
152.
Karanth, S.S., D.R. Springall, S. Lucas, D. Levy, P. Ashby, M.M. Levene, et al. Changes in nerves and neuropeptides in skin from 100 leprosy patients investigated by immunocytochemistry. J Pathol 1989;157:(1):15–26.
153.
Van Brakel, W.H., P.G. Nicholls, L. Das, P. Barkataki, P. Maddali, D.N. Lockwood, et al. The INFIR Cohort Study: assessment of sensory and motor neuropathy in leprosy at baseline. Lepr Rev 2005;76:(4):277–95.
154.
van Brakel, W.H., P.G. Nicholls, E.P. Wilder-Smith, L. Das, P. Barkataki, and D.N. Lockwood. Early diagnosis of neuropathy in leprosy--comparing diagnostic tests in a large prospective study (the INFIR cohort study). PLoS Negl Trop Dis 2008;2:(4):e212.
155.
Kumar, N., H.S. Malhotra, R.K. Garg, R. Lalla, K.P. Malhotra, A. Jain, et al. Comprehensive electrophysiology in leprous neuropathy - Is there a clinico-electrophysiological dissociation? Clin Neurophysiol 2016;127:(8):2747–2755.
156.
Chaurasia, R.N., R.K. Garg, M.K. Singh, R. Verma, and R. Shukla. Nerve conduction studies in paucibacillary and multibacillary leprosy: a comparative evaluation. Indian J Lepr 2011;83:(1):15–22.
157.
Husain, S. and G.N. Malaviya. Early nerve damage in leprosy: an electrophysiological study of ulnar and median nerves in patients with and without clinical neural deficits. Neurol India 2007;55:(1):22–6.
158.
Samant, G., V.P. Shetty, M.W. Uplekar, and N.H. Antia. Clinical and electrophysiological evaluation of nerve function impairment following cessation of multidrug therapy in leprosy. Lepr Rev 1999;70:(1):10–20.
159.
Soysal, A., T. Atay, T. Ozu, and B. Arpaci. Electrophysiological evaluation of peripheral and autonomic involvement in leprosy. Can J Neurol Sci 2004;31:(3):357–62.
160.
Villarroel, M.F., M.B. Orsini, M.A. Grossi, and C.M. Antunes. Impaired warm and cold perception thresholds in leprosy skin lesions. Lepr Rev 2007;78:(2):110–21.
161.
Jain, S., L.H. Visser, T.L. Praveen, P.N. Rao, T. Surekha, R. Ellanti, et al. High-resolution sonography: a new technique to detect nerve damage in leprosy. PLoS Negl Trop Dis 2009;3:(8):e498.
162.
Lugao, H.B., M.H. Nogueira-Barbosa, W. Marques, Jr., N.T. Foss, and M.A. Frade. Asymmetric Nerve Enlargement: A Characteristic of Leprosy Neuropathy Demonstrated by Ultrasonography. PLoS Negl Trop Dis 2015;9:(12):e0004276.
163.
Martinoli, C., L.E. Derchi, M. Bertolotto, N. Gandolfo, S. Bianchi, P. Fiallo, et al. US and MR imaging of peripheral nerves in leprosy. Skeletal Radiol 2000;29:(3):142–50.
164.
Akita, J., L.H.G. Miller, F.M.C. Mello, J.A. Barreto, A.L. Moreira, M.H. Salgado, et al. Comparison between nerve conduction study and high-resolution ultrasonography with color doppler in type 1 and type 2 leprosy reactions. Clin Neurophysiol Pract 2021;697–102.
165.
Sreejith, K., S. Sasidharanpillai, K. Ajithkumar, R.M. Mani, A.T. Chathoth, P.S. Menon, et al. High-resolution ultrasound in the assessment of peripheral nerves in leprosy: A comparative cross-sectional study. Indian J Dermatol Venereol Leprol 2021;87:(2):199–206.
166.
Illarramendi, X., S. Buhrer-Sekula, A.M. Sales, M.I. Bakker, A. Oliveira, J.A. Nery, et al. High prevalence of vasomotor reflex impairment in newly diagnosed leprosy patients. Eur J Clin Invest 2005;35:(10):658–65.
167.
Cavalheiro, A.L., D.T. Costa, A.L. Menezes, J.M. Pereira, and E.M. Carvalho. Thermographic analysis and autonomic response in the hands of patients with leprosy. An Bras Dermatol 2016;91:(3):274–83.
168.
Beck, J.S., N.C. Abbot, P.D. Samson, C.R. Butlin, J.M. Grange, I.A. Cree, et al. Impairment of vasomotor reflexes in the fingertips of leprosy patients. J Neurol Neurosurg Psychiatry 1991;54:(11):965–71.
Metadata
Title
Treatment and Evaluation Advances in Leprosy Neuropathy
Authors
Gigi J. Ebenezer
David M. Scollard
Publication date
01-10-2021
Publisher
Springer International Publishing
Keyword
Leprosy
Published in
Neurotherapeutics / Issue 4/2021
Print ISSN: 1933-7213
Electronic ISSN: 1878-7479
DOI
https://doi.org/10.1007/s13311-021-01153-z

Other articles of this Issue 4/2021

Neurotherapeutics 4/2021 Go to the issue

Original Article

Hybrid Nanoparticles as a Novel Tool for Regulating Psychosine-Induced Neuroinflammation and Demyelination In Vitro and Ex vivo

Original Article

REM Sleep Deprivation Impairs Learning and Memory by Decreasing Brain O-GlcNAc Cycling in Mouse

Review

Metabolic Transporters in the Peripheral Nerve—What, Where, and Why?

Correction

Correction to: Comparative Effectiveness and Tolerability of the Pharmacology of Monoclonal Antibodies Targeting the Calcitonin Gene-Related Peptide and Its Receptor for the Prevention of Chronic Migraine: a Network Meta-analysis of Randomized Controlled Trials

Original Article

Disease Reactivation after Fingolimod Discontinuation in Pregnant Multiple Sclerosis Patients

Editorial

Peripheral Neuropathy: No Longer the Land of Therapeutic Nihilism